title: Meningeal myelomatosis developed after treatment with novel agents.
authors: Department of Hematology-Oncology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba, Chiba, 260-8717, Japan, mise@chiba-cc.jp.
authors: Mikiko
authors: M
authors: Ise
authors: Chikara
authors: C
authors: Sakai
authors: Kyoya
authors: K
authors: Kumagai
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D002555:Cerebrospinal Fluid / Q000166:cytology*; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology*; D009101:Multiple Myeloma / Q000134:cerebrospinal fluid / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology*; D010950:Plasma Cells / Q000473:pathology*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone
references: Eur J Haematol. 2006 Apr;76(4):358-9
references: 16519710
references: Cancer. 2012 Mar 15;118(6):1574-84
references: 21932386
references: Br J Haematol. 2013 Jul;162(2):281-2
references: 23600765